This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Generic Name
- Anlotinib
- DrugBank Accession Number
- DB11885
- Background
Anlotinib has been investigated for the treatment of Non-small Cell Lung Cancer and Metastatic Colorectal Cancer.
- Type
- Small Molecule
- Groups
- Investigational
- Structure
- Weight
- Average: 407.445
Monoisotopic: 407.164519743 - Chemical Formula
- C23H22FN3O3
- Synonyms
- Not Available
- External IDs
- AL 3818
- AL-3818
- AL3818
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Contraindications & Blackbox Warnings
- Avoid life-threatening adverse drug eventsImprove clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events & improve clinical decision support.
- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
- Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.Improve decision support & research outcomes with our structured adverse effects data.
- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- Not Available
Categories
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as diarylethers. These are organic compounds containing the dialkyl ether functional group, with the formula ROR', where R and R' are aryl groups.
- Kingdom
- Organic compounds
- Super Class
- Organic oxygen compounds
- Class
- Organooxygen compounds
- Sub Class
- Ethers
- Direct Parent
- Diarylethers
- Alternative Parents
- Quinolines and derivatives / Indoles / Anisoles / Alkyl aryl ethers / Substituted pyrroles / Pyridines and derivatives / Aryl fluorides / Heteroaromatic compounds / Azacyclic compounds / Organofluorides show 2 more
- Substituents
- Alkyl aryl ether / Amine / Anisole / Aromatic heteropolycyclic compound / Aryl fluoride / Aryl halide / Azacycle / Benzenoid / Diaryl ether / Heteroaromatic compound show 15 more
- Molecular Framework
- Aromatic heteropolycyclic compounds
- External Descriptors
- Not Available
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- GKF8S4C432
- CAS number
- 1058156-90-3
- InChI Key
- KSMZEXLVHXZPEF-UHFFFAOYSA-N
- InChI
- InChI=1S/C23H22FN3O3/c1-13-9-15-16(27-13)3-4-19(22(15)24)30-18-5-8-26-17-11-21(20(28-2)10-14(17)18)29-12-23(25)6-7-23/h3-5,8-11,27H,6-7,12,25H2,1-2H3
- IUPAC Name
- 1-[({4-[(4-fluoro-2-methyl-1H-indol-5-yl)oxy]-6-methoxyquinolin-7-yl}oxy)methyl]cyclopropan-1-amine
- SMILES
- COC1=CC2=C(OC3=CC=C4NC(C)=CC4=C3F)C=CN=C2C=C1OCC1(N)CC1
References
- General References
- Not Available
- External Links
- PubChem Compound
- 25017411
- PubChem Substance
- 347828221
- ChemSpider
- 45743493
- ZINC
- ZINC000117924202
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Not Yet Recruiting Treatment Non-Small Cell Lung Carcinoma (NSCLC) 1 4 Recruiting Treatment Advanced Non Squamous NSCLC 1 4 Recruiting Treatment Head and Neck Carcinoma 1 4 Recruiting Treatment Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) 1 3 Not Yet Recruiting Treatment Anlotinib / Hepatocellular Carcinoma / PDL-1 / Thermal Ablation 1 3 Not Yet Recruiting Treatment Extensive Small Cell Lung Cancer 1 3 Not Yet Recruiting Treatment Non Small Cell Lung Cancer Squamous (NSCLC-Sq) 1 3 Not Yet Recruiting Treatment Small Cell Lung Cancer (SCLC) 1 3 Not Yet Recruiting Treatment Triple Negative Breast Cancer 1 3 Recruiting Treatment Advanced Renal Cancer 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
- Not Available
- Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Not Available
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source Water Solubility 0.00238 mg/mL ALOGPS logP 3.7 ALOGPS logP 3.35 ChemAxon logS -5.2 ALOGPS pKa (Strongest Acidic) 16.65 ChemAxon pKa (Strongest Basic) 9.39 ChemAxon Physiological Charge 1 ChemAxon Hydrogen Acceptor Count 4 ChemAxon Hydrogen Donor Count 2 ChemAxon Polar Surface Area 82.39 Å2 ChemAxon Rotatable Bond Count 6 ChemAxon Refractivity 110.65 m3·mol-1 ChemAxon Polarizability 42.95 Å3 ChemAxon Number of Rings 5 ChemAxon Bioavailability 1 ChemAxon Rule of Five Yes ChemAxon Ghose Filter Yes ChemAxon Veber's Rule No ChemAxon MDDR-like Rule Yes ChemAxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
Spectrum Spectrum Type Splash Key Predicted MS/MS Spectrum - 10V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Positive (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 10V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 20V, Negative (Annotated) Predicted LC-MS/MS Not Available Predicted MS/MS Spectrum - 40V, Negative (Annotated) Predicted LC-MS/MS Not Available
Drug created at October 20, 2016 20:57 / Updated at June 12, 2020 16:53